EU Panel Recommends Pembrolizumab/Chemo Combo in Squamous NSCLC

February 4, 2019 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for first-line treatment with pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel in patients with metastatic squamous non–small cell lung cancer (NSCLC). The decision is based on findings from the phase III KEYNOTE-407 trial, in which patients were enrolled regardless of PD-L1 … (leggi tutto)